On May 2, 2022, Abbott Laboratories announced that at its annual general meeting of shareholder held on April 29, 2022, the shareholders rejected a shareholder proposal that Abbott's Board of Directors prepare a report on the public health costs and financial market impacts of Abbott's standards and programs regarding antimicrobial resistance.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
106.9 USD | -0.65% | +0.93% | -2.89% |
Apr. 23 | Daiwa Securities Trims Abbott Laboratories Price Target to $125 From $126 | MT |
Apr. 22 | Barclays Adjusts Abbott Laboratories' Price Target to $140 From $141, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.89% | 187B | |
-2.43% | 108B | |
-4.10% | 67.71B | |
+11.10% | 53.07B | |
+15.86% | 47.36B | |
+6.01% | 39.73B | |
+9.55% | 28.56B | |
+1.85% | 26.55B | |
+15.97% | 25.13B | |
-0.44% | 24.97B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Declaration of Voting Results by Abbott Laboratories